The political economy of drug pricing operates on a simple mechanic: large headline numbers attract legislative attention, and WAC is the largest number available. When list prices rise sharply while rebates absorb most of the increase—leaving net manufacturer revenue roughly stable—the public policy debate focuses on the list price number, which is visible, rather than the rebate structure, which is not. The result is a regulatory environment that responds to the signal that MedPricer’s WAC data most directly tracks—list price inflation—while largely missing the mechanism that actually determines who pays what.
How WAC Increases Become Political Events
The pattern is well-documented: a manufacturer announces a list price increase, often in January or July when the industry traditionally implements WAC changes. The increase is reported in percentage terms—eight, ten, twelve percent. Healthcare reporters and advocacy organizations publish the WAC increase without reference to the net price impact. Members of Congress send letters to the manufacturer requesting justification. The manufacturer responds that net prices are flat or declining due to rebate increases.
Both the manufacturer and the critics are describing accurate but incomplete pictures. MedPricer’s WAC-ASP spread data offers a third frame: the observable spread between list price and the CMS-validated net price, trended over time, which provides an independent basis for assessing whether the manufacturer’s claim of flat net pricing is consistent with publicly available data.
When Spread Size Becomes a Policy Trigger
Not all WAC-ASP spreads generate policy attention, but very large ones consistently do. When the spread between list price and effective price for a drug reaches fifty, sixty, or seventy percent—implying that the drug’s net price is a fraction of its list price—it raises structural questions about the pricing system’s transparency and efficiency that go beyond any individual drug’s controversy.
MedPricer’s dataset, if tracked systematically across the drug universe, would reveal which drugs and therapeutic categories have the largest WAC-ASP spreads—which are, effectively, the drugs with the most politically vulnerable pricing structures. An investor holding a pharmaceutical company whose flagship product has a large and growing WAC-ASP spread is holding a policy risk as well as a business risk. The regulatory and legislative attention that follows very large spreads is not random: it is predictable from the data.
The Bipartisan Rebate Problem
Drug pricing policy has been one of the few genuinely bipartisan issues in recent American politics, which reflects the broad public salience of high list prices rather than broad legislative agreement on how to address them. Republicans and Democrats agree that list prices are too high and that the rebate system is opaque; they disagree substantially on what to do about it. The legislative proposals have ranged from rebate passthrough requirements (primarily Republican, targeting PBM retention of rebates) to direct price controls (primarily Democratic, targeting manufacturer list prices) to negotiation mechanisms (the IRA approach).
What all these approaches share is a dependence on the WAC-ASP spread as the empirical basis for policy urgency. Without data showing that list prices diverge substantially from effective prices—and without time-series data showing that the divergence is growing—the policy case for intervention is harder to make. MedPricer’s dataset is, in a narrow but specific sense, the kind of empirical infrastructure that drug pricing policy debates have lacked.
The Manufacturer Calculus and Its Limits
Manufacturers who expand rebate structures to defend formulary position while raising WAC are making a rational short-term business decision: maintain volume at the cost of increased gross-to-net, rather than sacrifice volume by resisting PBM formulary demands. The accumulation of these individual decisions across the industry produces a market structure with systematically high WAC, systematically deep rebates, and a political environment that misreads the resulting list prices as evidence of manufacturer pricing power rather than rebate complexity.
The limit of this strategy is not just political—it is financial. Very large gross-to-net adjustments create earnings visibility problems, complicate financial guidance, and expose manufacturers to revenue surprise risk when payer mix shifts or rebate arrangements are renegotiated. A manufacturer optimizing individual contracting decisions without modeling the portfolio-level gross-to-net exposure is building a financial structure that is difficult to communicate to investors and difficult to defend when the political environment turns hostile.
